Stockscreener 앱 받기
7.91
3.54%
-0.29
시간 외 거래:
7.91
전일 마감가:
$8.20
열려 있는:
$8.34
하루 거래량:
967.10K
Relative Volume:
0.37
시가총액:
$467.54M
수익:
$192.64M
순이익/손실:
$2.51M
주가수익비율:
150.95
EPS:
0.0524
순현금흐름:
$12.42M
1주 성능:
-8.02%
1개월 성능:
+9.41%
6개월 성능:
+71.58%
1년 성능:
+54.19%
1일 변동 폭
$7.77
$8.38
1주일 범위
$7.66
$9.005
52주 변동 폭
$3.8092
$9.60
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
명칭
Vanda Pharmaceuticals Inc
전화
202-734-3400
주소
2200 PENNSYLVANIA AVE NW, WASHINGTON
Compare VNDA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
7.91 | 484.69M | 192.64M | 2.51M | 12.42M | 0.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-05 | 개시 | B. Riley Securities | Buy |
| 2024-10-31 | 개시 | H.C. Wainwright | Buy |
| 2024-07-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-02-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-05-12 | 개시 | BofA Securities | Buy |
| 2021-01-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-06-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-03-16 | 다운그레이드 | Oppenheimer | Perform → Underperform |
| 2020-03-12 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-11-07 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-08-01 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-07-25 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-12-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2018-12-04 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | 재확인 | Jefferies | Buy |
| 2018-11-08 | 재개 | Jefferies | Buy |
| 2018-09-21 | 재개 | Oppenheimer | Outperform |
| 2018-05-23 | 개시 | Citigroup | Buy |
| 2018-01-19 | 개시 | Seaport Global Securities | Buy |
| 2017-09-14 | 재확인 | Piper Jaffray | Overweight |
| 2017-06-27 | 재개 | Piper Jaffray | Overweight |
| 2017-05-26 | 개시 | H.C. Wainwright | Buy |
| 2017-04-12 | 개시 | Oppenheimer | Outperform |
| 2016-11-09 | 개시 | Aegis Capital | Buy |
| 2016-10-06 | 재개 | Jefferies | Buy |
모두보기
Vanda Pharmaceuticals Inc 주식(VNDA)의 최신 뉴스
Truist Financial Begins Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat
Truist Securities Initiates Coverage on Vanda Pharmaceuticals (V - GuruFocus
Truist initiates Vanda Pharmaceuticals stock at buy on drug pipeline - Investing.com
Truist Initiates Vanda Pharmaceuticals at Buy With $18 Price Target - marketscreener.com
Vanda Pharmaceuticals (NASDAQ:VNDA) CMO Joakim Wijkstrom Sells 30,800 Shares - MarketBeat
Kevin Patrick Moran Sells 42,442 Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) Stock - MarketBeat
Insider Selling: Vanda Pharmaceuticals (NASDAQ:VNDA) SVP Sells 42,434 Shares of Stock - MarketBeat
Gunther Birznieks Sells 42,431 Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) Stock - MarketBeat
Insider Selling: Vanda Pharmaceuticals (NASDAQ:VNDA) CEO Sells 156,235 Shares of Stock - MarketBeat
Vanda Pharmaceuticals (VNDA) SVP sells 42,431 shares to cover RSU tax - Stock Titan
VNDA SEC FilingsVanda Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Q1 Earnings Estimate for VNDA Issued By HC Wainwright - MarketBeat
VNDA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
FDA Grants Rare Hearing for Vanda Pharmaceuticals' (VNDA) Jet La - GuruFocus
Vanda Now Looks To Public Hearing For Hetlioz In Jet Lag Disorder After Multiple FDA Rejections - Stocktwits
After years of dispute with FDA, Vanda will get a public hearing for jet lag drug - Endpoints News
Vanda secures win in regulatory showdown as FDA agrees to review jet lag drug - The Business Journals
Vanda announces FDA grants landmark hearing for Hetlioz® in jet lag disorder, the first drug approval hearing in over 40 years - marketscreener.com
Vanda Pharmaceuticals Wins Rare FDA Hearing on HETLIOZ Application for Jet Lag - marketscreener.com
Vanda Pharmaceuticals (VNDA) Secures Rare FDA Hearing for Hetlio - GuruFocus
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years - Finviz
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years - ChartMill
Vanda Pharmaceuticals (NASDAQ:VNDA) Share Price Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
[144] Vanda Pharmaceuticals Inc. SEC Filing - Stock Titan
VNDA Earnings History & Surprises | EPS & Revenue Results | VANDA PHARMACEUTICALS INC (NASDAQ:VNDA) - ChartMill
EMA Turns Down Vanda’s Iloperidone And Acadia’s Daybu, Backs 12 Others For EU Approval - Citeline News & Insights
Vanda Pharmaceuticals Receives Negative Opinion From European Medicines Agency's CHMP for Iloperidone - marketscreener.com
Vanda Pharmaceuticals to Participate in 2026 Citizens Life Sciences Conference - Intellectia AI
Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference - ChartMill
A Look At Vanda Pharmaceuticals (VNDA) Valuation After FDA Approval Of Bysanti For Bipolar I Disorder And Schizophrenia - simplywall.st
Vanda Pharmaceuticals price target raised to $17 from $14 at B. Riley - Yahoo Finance
Vanda Pharmaceuticals Inc. (VNDA) Stock Analysis: A Biotech Contender with Nearly 80% Upside Potential - DirectorsTalk Interviews
Vanda Pharmaceuticals Breaks Through With FDA Approval, Decision Date For Skin Drug - Benzinga
Vanda skin disorder drug accepted for FDA review - MSN
Vanda Pharmaceuticals Says US FDA Accepts Imsidolimab BLA for Rare Skin Disease - marketscreener.com
Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder - Asianet Newsable
B. Riley Adjusts Vanda Pharmaceuticals Price Target to $17 From $14, Maintains Buy Rating - marketscreener.com
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis - The Malaysian Reserve
Vanda Pharmaceuticals Seeks FDA Approval for Imsidolimab - Intellectia AI
Vanda Pharmaceuticals (VNDA) Gains on FDA Review Acceptance for Imsidolimab - GuruFocus
Vanda Pharmaceuticals Files BLA for Imsidolimab to Treat GPP - Intellectia AI
Vanda skin disorder drug accepted for FDA review (VNDA:NASDAQ) - Seeking Alpha
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics Lice - GuruFocus
Insider Sell: Tage Honore Sells 30,000 Shares of Vanda Pharmaceu - GuruFocus
Director Honore Tage sells 30,000 Vanda (NASDAQ: VNDA) shares at $8.03 - Stock Titan
What's Going On With Vanda Pharma Stock Tuesday? - Bitget
VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains? - Stocktwits
Vanda Pharmaceuticals stock price target raised to $24 by H.C. Wainwright on FDA approval - Investing.com UK
Insider files Form 144 to sell 30,000 Vanda Pharma shares (VNDA) - Stock Titan
Vanda Pharmaceuticals stock jumps 41% on Bysanti FDA approval filing as analysts weigh uptake risk - Bez Kabli
Vanda Pharmaceuticals scores second FDA approval in 2 months - The Business Journals
Vanda Pharmaceuticals Inc (VNDA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Vanda Pharmaceuticals Inc 주식 (VNDA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Moran Kevin Patrick | SVP, CFO & Treasurer |
Mar 02 '26 |
Sale |
8.27 |
42,442 |
350,821 |
411,380 |
| Wijkstrom Joakim | SVP, Chief Marketing Officer |
Mar 02 '26 |
Sale |
8.27 |
30,800 |
254,590 |
333,469 |
| Polymeropoulos Mihael Hristos | President and CEO |
Mar 02 '26 |
Sale |
8.17 |
156,235 |
1,276,971 |
2,704,496 |
| Birznieks Gunther | SVP, Business Development |
Mar 02 '26 |
Sale |
8.27 |
42,431 |
350,730 |
494,197 |
3.69%
0.71%
자본화:
|
볼륨(24시간):